Compare EARN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | FHTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 173.4M |
| IPO Year | 2012 | 2020 |
| Metric | EARN | FHTX |
|---|---|---|
| Price | $3.43 | $2.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | 398.9K | ★ 987.0K |
| Earning Date | 08-12-2026 | 11-04-2026 |
| Dividend Yield | ★ 26.89% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $19.35 | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $3.42 | $1.79 |
| 52 Week High | $5.72 | $7.61 |
| Indicator | EARN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.08 | 16.48 |
| Support Level | N/A | N/A |
| Resistance Level | $4.45 | $5.35 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | -0.08 | -0.16 |
| Stochastic Oscillator | 13.46 | 12.43 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.